This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (26) Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Reynolds, G. P. Search for Related Content PubMed PubMed Citation Articles by Reynolds, G. P. Social Bookmarking                         What's this?

Receptor Mechanisms in the treatment of Schizophrenia

Department of Mental Health, Queen’s University Belfast, Belfast, UK.g.reynolds{at}qub.ac.uk

There remain many limitations to the treatment of schizophrenia. In addition to the poor response of negative and cognitive symptoms to antipsychotics, and the substantial proportion of poor- or non-responders, there are a variety of unpleasant and restricting side-effects of these drugs. The introduction of several ‘atypical’ drugs, with diminished propensity to cause extrapyramidal motor effects (EPS), has greatly improved the tolerability of antipsychotic treatments. The pharmacology of atypical antipsychotics is varied and, although dopamine D₂ receptor antagonism is common to all antipsychotics, the mechanisms of a typicality are complex and not fully understood. Thus, antagonism at 5-HT₂ and/or other receptors, weak dopamine receptor affinity and, most recently, partial agonism at dopamine D₂ receptors, have been variously implicated. However, because EPS have diminished with improvements in drug treatment, drug-induced weight gain has emerged as a majorconcern, and the pharmacological basis of this problem, involving effects at 5-HT_2c and perhaps other receptors, is yielding toinvestigation. Some drugs, notably the D₂ partial agonists, can provide antipsychotic effects without the emergence of several of the seproblematic side-effects, which bodes well for future treatment.

Key Words: atypical antipsychotic • D2 receptor partial agonism • dopamine • 5-HT1A receptor • 5-HT2 receptors • schizophrenia

Journal of Psychopharmacology, Vol. 18, No. 3, 340-345 (2004)
DOI: 10.1177/026988110401800303


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				J. C. Nelson and G. I. Papakostas Atypical Antipsychotic Augmentation in Major Depressive Disorder: A Meta-Analysis of Placebo-Controlled Randomized Trials Am J Psychiatry, September 1, 2009; 166(9): 980 - 991. [Abstract] [Full Text] [PDF]

				L Dahan, H Husum, O Mnie-Filali, J Arnt, P Hertel, and N Haddjeri Effects of bifeprunox and aripiprazole on rat serotonin and dopamine neuronal activity and anxiolytic behaviour J Psychopharmacol, March 1, 2009; 23(2): 177 - 189. [Abstract] [PDF]

				C. K. Jones, A. E. Brady, A. A. Davis, Z. Xiang, M. Bubser, M. N. Tantawy, A. S. Kane, T. M. Bridges, J. P. Kennedy, S. R. Bradley, et al. Novel Selective Allosteric Activator of the M1 Muscarinic Acetylcholine Receptor Regulates Amyloid Processing and Produces Antipsychotic-Like Activity in Rats J. Neurosci., October 8, 2008; 28(41): 10422 - 10433. [Abstract] [Full Text] [PDF]

				S. Snigdha, C. Thumbi, G. Reynolds, and J. Neill Ziprasidone and aripiprazole attenuate olanzapine-induced hyperphagia in rats J Psychopharmacol, July 1, 2008; 22(5): 567 - 571. [Abstract] [PDF]

				O. O. Yevtushenko, S. J. Cooper, R. O'Neill, J. K. Doherty, J. V. Woodside, and G. P. Reynolds Influence of 5-HT2C receptor and leptin gene polymorphisms, smoking and drug treatment on metabolic disturbances in patients with schizophrenia The British Journal of Psychiatry, June 1, 2008; 192(6): 424 - 428. [Abstract] [Full Text] [PDF]

				D. C. Owens What CATIE Did: Some Thoughts on Implications Deep and Wide Psychiatr Serv, May 1, 2008; 59(5): 530 - 533. [Abstract] [Full Text] [PDF]

				D. C. Owens How CATIE brought us back to Kansas: a critical re-evaluation of the concept of atypical antipsychotics and their place in the treatment of schizophrenia Adv. Psychiatr. Treat., January 1, 2008; 14(1): 17 - 28. [Abstract] [Full Text] [PDF]

				S. Jordan, K. Regardie, J. L. Johnson, Ruoyan Chen, J. Kambayashi, R. McQuade, H. Kitagawa, Y. Tadori, and T. Kikuchi In vitro functional characteristics of dopamine D2 receptor partial agonists in second and third messenger-based assays of cloned human dopamine D2Long receptor signalling J Psychopharmacol, August 1, 2007; 21(6): 620 - 627. [Abstract] [PDF]

				A. Leanos-Miranda, A. Ulloa-Aguirre, L. A Cervini, J. A. Janovick, J. Rivier, and P M. Conn Identification of new gonadotrophin-releasing hormone partial agonists. J. Endocrinol., June 1, 2006; 189(3): 509 - 517. [Abstract] [Full Text] [PDF]